Literature DB >> 11839381

Clone and expression of mutant M-CSF and its receptor from human leukemic cell line J6-1.

Ge Li1, Yu-Hua Song, Ke-Fu Wu, Yong-Min Lin, Zhen-Yu Cao, Guo-Guang Zheng.   

Abstract

Macrophage colony-stimulating factor (M-CSF) plays important roles in hematopoietic and immunologic systems. Some isoforms or mutations have been demonstrated including membrane-bound and cellular M-CSF, which associated with some leukemia, lymphoma and other solid tumors. We previously reported that the M-CSF-like membrane-associated factor (MAF-J6-1) and its receptor was found from human leukemic cell line J6-1. In this report, the cDNA of MAF-J6-1 and its receptor were cloned. The cDNA sequence of MAF-J6-1 shows a 768bp open reading frame (ORF) with 99.2% homology to m-M-CSF, but six site mutations, including two synonymous mutations and four missense mutations. The cDNA of MAF-J6-1-R has a 2916bp ORF shared 99.6% homology with M-CSF-R, but 13 site mutations, including six synonymous mutations and seven missense mutations. At the same time, a 1662bp mutant s-M-CSF cDNA, which has 10 site mutations including three synonymous mutations and seven missense mutations, was cloned from J6-1 cells. The cDNAs of MAF-J6-1 and MAF-J6-1-R were inserted into a mammalian expression plasmid pTARGET and were expressed in COS-7 cells that demonstrated by their specific MAb. COS-7 cells transfected with MAF-J6-1-R show obvious protein tyrosine kinase (PTK) activity. Our present work shows that MAF-J6-1 and its receptor are mutations of M-CSF and its receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839381     DOI: 10.1016/s0145-2126(01)00139-4

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  1 in total

1.  Enhanced recombinant M-CSF production in CHO cells by glycerol addition: model and validation.

Authors:  Chi-Hsien Liu; Li-Hsin Chen
Journal:  Cytotechnology       Date:  2007-06-13       Impact factor: 2.058

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.